Feline Macrophage Activation Syndrome: Diagnosis and Management

Macrophage activation syndrome (MAS) is a severe, life-threatening hyperinflammatory condition that can develop in cats as a complication of underlying inflammatory, infectious, or neoplastic diseases. This article provides veterinarians with evidence-based guidance on recognizing the clinical presentation, applying diagnostic criteria, and implementing appropriate management strategies for feline MAS. The condition is characterized by uncontrolled activation and proliferation of macrophages and T lymphocytes, leading to a cytokine storm that causes fever, hepatosplenomegaly, cytopenias, and multiorgan dysfunction. Prompt recognition and intervention are critical for improving patient outcomes.

At a Glance

Pathophysiology and Etiology

Macrophage activation syndrome represents a dysregulated immune response in which activated macrophages and T lymphocytes produce excessive proinflammatory cytokines, creating a self-amplifying inflammatory loop. In cats, this syndrome is most commonly secondary to underlying diseases instead of a primary genetic disorder, distinguishing it from primary hemophagocytic lymphohistiocytosis seen in humans and some dog breeds.

Cytokine Storm Mechanisms

The hallmark of MAS is a cytokine storm driven by uncontrolled activation of CD8+ T lymphocytes and macrophages. Activated T cells produce large amounts of interferon-gamma (IFN-gamma), which stimulates macrophages to release interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and other inflammatory mediators. These cytokines further activate T cells and macrophages, perpetuating the cycle. The resulting hyperinflammation causes tissue damage, particularly in the liver, spleen, bone marrow, and lymph nodes.

The cytokine profile in MAS shares similarities with other hyperinflammatory syndromes, including cytokine release syndrome (CRS) and hemophagocytic lymphohistiocytosis (HLH) associated with immune effector cell therapies in human medicine. Research on immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) describes similar elevations in serum ferritin, hepatic transaminases, decreasing cell counts, and hypofibrinogenemia as surrogate indicators of hyperinflammation (source: Hematology/Oncology Clinics of North America, 2025, https://doi.org/10.1016/j.hoc.2025.02.005). These parallels suggest that the underlying inflammatory pathways may be conserved across species and triggers.

Underlying Triggers in Cats

Several underlying conditions can trigger MAS in cats. Infectious diseases are common triggers, including feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), feline infectious peritonitis (FIP), hemoplasmosis, toxoplasmosis, and systemic fungal infections. The interaction between FIV and CD134, a costimulatory molecule on T cells, has been studied and may contribute to immune dysregulation in infected cats (source: Journal of Virology, 2007, https://pubmed.ncbi.nlm.nih.gov/17609274). Neoplastic diseases, particularly lymphoma and histiocytic disorders such as Langerhans cell histiocytosis, can also precipitate MAS. In human pediatric patients with Langerhans cell histiocytosis and MAS-HLH, the condition is associated with young age, risk organ involvement, and BRAF-V600E mutations (source: Orphanet Journal of Rare Diseases, 2022, https://doi.org/10.1186/s13023-022-02276-y). Inflammatory diseases such as immune-mediated hemolytic anemia, polyarthritis, and pancreatitis are additional potential triggers.

In some cases, no underlying trigger is identified despite thorough diagnostic investigation. These idiopathic cases present a particular challenge, as treatment must focus on controlling the hyperinflammatory state while continuing to search for an occult trigger.

Clinical Presentation and Physical Examination Findings

The clinical signs of MAS in cats are often nonspecific and overlap with those of the underlying disease, making diagnosis challenging. A high index of suspicion is necessary, particularly in cats with persistent fever and cytopenias that do not respond to standard therapy.

Fever and Systemic Signs

Persistent fever is the most consistent clinical sign in feline MAS. The fever is typically high (103.5-106.0 degrees Fahrenheit or 39.7-41.1 degrees Celsius), unresponsive to broad-spectrum antibiotics, and may follow a relapsing-remitting pattern. Affected cats often appear lethargic, anorexic, and depressed. Weight loss and dehydration are common due to prolonged illness and reduced food intake.

Organomegaly and Lymphadenopathy

Hepatosplenomegaly is a hallmark finding in MAS. The liver and spleen may be palpably enlarged on abdominal examination. Abdominal ultrasound can confirm organomegaly and may reveal diffuse parenchymal changes, including increased echogenicity of the liver and spleen. Lymphadenopathy, particularly involving the peripheral lymph nodes, is also common. Enlarged lymph nodes may be firm but are typically not painful on palpation.

Mucous Membrane and Skin Changes

Pallor of the mucous membranes may be present due to anemia. Petechiae and ecchymoses can develop secondary to thrombocytopenia and coagulopathy. Jaundice may occur in cats with significant hepatic involvement or hemolysis. Skin changes are less common but may include erythema, edema, or ulcerative lesions in severe cases.

Neurologic Signs

Neurologic signs can occur in cats with MAS, particularly when the central nervous system is involved. Seizures, ataxia, altered mentation, and cranial nerve deficits have been reported. Neurologic involvement may result from direct infiltration of activated macrophages into the central nervous system, cytokine-mediated neurotoxicity, or secondary to coagulopathy and hemorrhage.

Diagnostic Approach

A systematic diagnostic approach is essential for confirming MAS, identifying the underlying trigger, and assessing the severity of organ involvement. The diagnosis is based on a combination of clinical signs, laboratory abnormalities, and specific biomarker findings.

Minimum Database

Complete blood count (CBC), serum biochemistry profile, and urinalysis should be performed in all suspected cases. The CBC typically reveals cytopenias affecting at least two cell lines. Anemia is common and may be nonregenerative due to bone marrow suppression or hemophagocytosis. Thrombocytopenia is present in most cases, and leukopenia, particularly neutropenia, is also frequently observed. Pancytopenia may develop in severe or advanced cases.

Serum biochemistry findings often include elevated liver enzymes (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase), hyperbilirubinemia, and hypoalbuminemia. Elevated blood urea nitrogen and creatinine may indicate prerenal azotemia from dehydration or renal involvement. Coagulation abnormalities, including prolonged prothrombin time and activated partial thromboplastin time, are common due to consumptive coagulopathy and hepatic dysfunction.

Specific Biomarkers

Serum ferritin is the most useful biomarker for diagnosing MAS in cats. Hyperferritinemia reflects macrophage activation and is a key diagnostic criterion. Ferritin levels are typically markedly elevated, often exceeding 500-1000 ng/mL, and may reach much higher values in severe cases. Serial monitoring of ferritin can be used to assess response to therapy, as declining levels indicate successful immunosuppression.

Soluble CD25 (sCD25), also known as soluble interleukin-2 receptor alpha, is another important biomarker. sCD25 is released by activated T lymphocytes and is elevated in MAS. While sCD25 testing is not as widely available as ferritin measurement, it provides additional diagnostic specificity when available. Elevated sCD25 levels help differentiate MAS from other causes of fever and cytopenias.

Other biomarkers that may be elevated include lactate dehydrogenase, triglycerides, and D-dimer. Hypofibrinogenemia is a concerning finding that indicates consumptive coagulopathy and is associated with more severe disease.

Bone Marrow Aspiration and Biopsy

Bone marrow aspiration is a critical diagnostic step in suspected MAS. The bone marrow typically shows hemophagocytosis, with macrophages actively engulfing erythrocytes, leukocytes, and platelets. Other findings may include myeloid hyperplasia, erythroid hyperplasia, or dysplasia. In some cases, the bone marrow may appear hypocellular due to extensive hemophagocytosis and destruction of hematopoietic precursors.

Bone marrow biopsy provides additional information about cellularity, fibrosis, and the presence of infiltrative diseases such as lymphoma or histiocytic disorders. Immunohistochemistry can help characterize the macrophage population and identify specific markers such as CD163 and CD204.

Diagnostic Imaging

Abdominal ultrasound is useful for evaluating hepatosplenomegaly, lymphadenopathy, and other abdominal abnormalities. Thoracic radiographs may reveal pulmonary infiltrates, pleural effusion, or mediastinal lymphadenopathy. Advanced imaging such as computed tomography (CT) can provide more detailed assessment of organ involvement and help guide biopsy procedures.

Infectious Disease Testing

Comprehensive infectious disease testing is essential for identifying potential triggers. Testing should include FeLV antigen and FIV antibody testing, FIP coronavirus serology and reverse transcription polymerase chain reaction (RT-PCR), hemoplasma PCR, Toxoplasma serology and PCR, and fungal antigen testing (cryptococcal antigen, Aspergillus galactomannan) in endemic areas. Blood cultures should be performed if bacterial sepsis is suspected.

Histopathology of Affected Tissues

Biopsy of affected organs, such as liver, spleen, or lymph nodes, can provide evidence of macrophage infiltration and hemophagocytosis. Histopathology typically shows sinusoidal infiltration by activated macrophages, hemophagocytosis, and tissue necrosis. Immunohistochemistry for macrophage markers (CD163, CD204, Iba-1) can confirm the macrophage origin of infiltrating cells.

Diagnostic Criteria

While validated diagnostic criteria for MAS in cats have not been established, criteria adapted from human medicine and canine studies can be applied. The diagnosis requires the presence of fever, cytopenias affecting at least two cell lines, and at least one of the following: hyperferritinemia, elevated sCD25, or hemophagocytosis on bone marrow aspirate or tissue biopsy.

Major Criteria

Major criteria include fever (temperature greater than 103.5 degrees Fahrenheit or 39.7 degrees Celsius) for more than 7 days despite appropriate antimicrobial therapy, cytopenias affecting at least two of three cell lines (hemoglobin less than 10 g/dL, platelets less than 100,000/microliter, neutrophils less than 1,500/microliter), and hemophagocytosis in bone marrow, spleen, or lymph nodes.

Minor Criteria

Minor criteria include hyperferritinemia (greater than 500 ng/mL), elevated sCD25 (greater than 2,400 U/mL), elevated liver enzymes (ALT greater than 100 U/L, AST greater than 100 U/L), elevated lactate dehydrogenase (greater than 1,000 U/L), hypofibrinogenemia (less than 150 mg/dL), hypertriglyceridemia (greater than 200 mg/dL), and hepatosplenomegaly on imaging.

Diagnostic Algorithm

A diagnosis of MAS can be made when a cat meets all three major criteria or two major criteria plus at least three minor criteria. The presence of an underlying trigger should be documented when possible, but the absence of an identifiable trigger does not exclude the diagnosis.

Differential Diagnoses

Several conditions can mimic MAS and must be considered in the differential diagnosis. Immune-mediated hemolytic anemia (IMHA) can cause anemia, fever, and jaundice but typically lacks the pancytopenia and hyperferritinemia seen in MAS. Systemic lupus erythematosus (SLE) can cause fever, cytopenias, and organ involvement but is rare in cats and usually presents with other characteristic findings such as polyarthritis and glomerulonephritis.

Sepsis can cause fever, cytopenias, and organ dysfunction but is typically associated with positive blood cultures and a different cytokine profile. Hemophagocytic histiocytic sarcoma is a neoplastic proliferation of macrophages that can mimic MAS but is characterized by a solitary or multiple mass lesions instead of diffuse organ infiltration.

Primary bone marrow disorders such as myelodysplasia, aplastic anemia, and leukemia can cause cytopenias but lack the fever and hyperferritinemia of MAS. Drug reactions and toxin exposures should also be considered, particularly if there is a history of recent medication administration or environmental exposure.

Treatment and Management

The treatment of MAS in cats requires a multipronged approach targeting the hyperinflammatory state, providing supportive care, and addressing the underlying trigger. Immunosuppressive therapy is the cornerstone of treatment and should be initiated as soon as the diagnosis is confirmed or strongly suspected.

Immunosuppressive Therapy

High-dose corticosteroids are the first-line immunosuppressive agents for MAS. Dexamethasone (0.2-0.4 mg/kg intravenously every 12-24 hours) or prednisolone (2-4 mg/kg orally every 12-24 hours) are commonly used. Corticosteroids suppress the production of proinflammatory cytokines and inhibit macrophage and T-cell activation. Response to corticosteroid therapy should be assessed within 48-72 hours, with improvement in fever, cytopenias, and ferritin levels indicating a favorable response.

Cyclosporine is often added as a second immunosuppressive agent, particularly in cats that do not respond adequately to corticosteroids alone. Cyclosporine inhibits T-cell activation by blocking calcineurin and reducing IL-2 production. The typical dose is 5-10 mg/kg orally every 12-24 hours, with therapeutic drug monitoring recommended to maintain trough levels in the therapeutic range (300-500 ng/mL).

Other immunosuppressive agents that may be considered in refractory cases include mycophenolate mofetil, azathioprine, and leflunomide. These agents have been used in human and canine MAS but experience in cats is limited. Cytotoxic agents such as etoposide and cyclophosphamide are used in severe human HLH but carry significant toxicity risks and are rarely used in cats. In human patients with secondary hemophagocytic syndrome, etoposide treatment has been associated with increased occurrence of healthcare-associated infections, while no association with survival was found (source: Annals of Intensive Care, 2022, https://doi.org/10.1186/s13613-022-01075-9).

Supportive Care

Supportive care is essential for managing complications and maintaining organ function during immunosuppressive therapy. Intravenous fluid therapy with balanced crystalloid solutions should be provided to correct dehydration and maintain perfusion. Blood product transfusion may be necessary for severe anemia (packed red blood cells) or thrombocytopenia with active bleeding (platelet-rich plasma or fresh whole blood).

Antimicrobial therapy should be administered if there is evidence of concurrent infection. Broad-spectrum antibiotics are indicated in febrile cats pending culture results. Antiviral therapy may be considered in cats with documented FeLV or FIV infection, although evidence for efficacy in MAS is limited. Antifungal therapy is indicated if systemic fungal infection is identified.

Nutritional support is critical, as affected cats are often anorexic and catabolic. Nasoesophageal or esophageal feeding tubes should be placed in cats that are not eating adequately. Enteral nutrition is preferred over parenteral nutrition due to lower complication rates and better maintenance of gut barrier function.

Treatment of Underlying Trigger

Identifying and treating the underlying trigger is essential for long-term control of MAS. If an infectious trigger is identified, appropriate antimicrobial therapy should be initiated. For neoplastic triggers, chemotherapy or targeted therapy may be indicated. In human pediatric patients with Langerhans cell histiocytosis and MAS-HLH, targeted therapy with the BRAF inhibitor dabrafenib has shown promise for BRAF-V600E-positive patients, with prompt resolution of MAS signs and symptoms and less toxicity than second-line chemotherapy (source: Orphanet Journal of Rare Diseases, 2022, https://doi.org/10.1186/s13023-022-02276-y).

In cats with inflammatory triggers such as immune-mediated hemolytic anemia or polyarthritis, immunosuppressive therapy for the underlying condition should be optimized. In idiopathic cases, long-term immunosuppression may be necessary to maintain remission.

Monitoring and Adjusting Therapy

Close monitoring is essential during the treatment of MAS. Clinical parameters such as temperature, appetite, and mentation should be assessed daily. Laboratory monitoring should include CBC, serum biochemistry, and ferritin levels every 2-3 days initially, then weekly as the condition stabilizes.

Response to therapy is indicated by resolution of fever, improvement in cytopenias, and declining ferritin levels. If there is no improvement within 48-72 hours of initiating corticosteroid therapy, additional immunosuppressive agents should be added. If there is no response to combination therapy within 5-7 days, alternative diagnoses should be reconsidered and referral to a specialist is recommended.

Once remission is achieved, immunosuppressive therapy should be gradually tapered over several weeks to months. Relapse can occur during tapering, particularly if the underlying trigger has not been adequately controlled. Long-term monitoring is necessary to detect early signs of relapse.

Prognosis and Outcomes

The prognosis for cats with MAS is guarded to poor, with reported mortality rates of 50-70% even with appropriate treatment. Factors associated with a worse prognosis include severe pancytopenia, marked hyperferritinemia, coagulopathy, multiorgan dysfunction, and failure to identify or treat the underlying trigger.

Cats that respond to immunosuppressive therapy within the first week have a better prognosis. Complete recovery is possible in some cases, particularly when the underlying trigger can be effectively treated. However, many cats require long-term immunosuppression and remain at risk for relapse.

Common Failure Patterns

Several common failure patterns can compromise the successful management of MAS in cats. Delayed diagnosis is the most frequent failure, as the nonspecific clinical signs are often attributed to other conditions such as infection or immune-mediated disease. A high index of suspicion and early testing for ferritin and sCD25 can reduce diagnostic delays.

Inadequate immunosuppression is another common failure. Some cats require higher doses of corticosteroids or additional immunosuppressive agents to achieve remission. Failure to escalate therapy in nonresponders leads to progressive disease and poor outcomes.

Failure to identify and treat the underlying trigger is a major cause of treatment failure. Even with effective immunosuppression, MAS will recur if the trigger persists. Thorough diagnostic investigation for infectious, neoplastic, and inflammatory triggers is essential.

Inadequate supportive care, particularly failure to provide nutritional support and blood product transfusion, can lead to complications such as sepsis, bleeding, and organ failure. Close monitoring and proactive management of complications are critical for successful outcomes.

Professional Escalation Criteria

Veterinarians should consider referral to a veterinary internist or specialist center in the following situations: failure to respond to initial immunosuppressive therapy within 48-72 hours, development of severe complications such as disseminated intravascular coagulation, acute kidney injury, or respiratory failure, need for advanced diagnostic testing such as bone marrow biopsy or immunohistochemistry, suspicion of an underlying neoplastic trigger requiring chemotherapy, and recurrent or refractory disease requiring long-term management.

Practical Decision Framework for Treatment Escalation and Response Assessment in Feline Macrophage Activation Syndrome

Managing feline macrophage activation syndrome requires a structured approach to treatment decisions, as the condition can deteriorate rapidly and response to therapy is time-sensitive. A practical decision framework helps veterinarians systematically evaluate patient status, escalate therapy appropriately, and recognize when referral is necessary. This section provides a step-by-step framework for treatment escalation, a record system for tracking response, and troubleshooting methods for common clinical scenarios.

Treatment Escalation Framework

The treatment of feline MAS follows a tiered approach based on disease severity and response to initial therapy. The framework below outlines specific criteria for each treatment level and guidance on when to advance to the next tier.

Tier 1: Initial Immunosuppression

Tier 1 therapy is appropriate for cats with confirmed or strongly suspected MAS who are hemodynamically stable and have no evidence of severe organ dysfunction. The cornerstone of Tier 1 therapy is high-dose corticosteroids. Dexamethasone at 0.2-0.4 mg/kg intravenously every 12-24 hours or prednisolone at 2-4 mg/kg orally every 12-24 hours should be initiated immediately after diagnostic samples are collected.

Response assessment should occur at 48-72 hours. Criteria for adequate response include resolution of fever (temperature below 103.0 degrees Fahrenheit or 39.4 degrees Celsius), improvement in mentation and appetite, stabilization or improvement in cell counts (hemoglobin stable or rising, platelet count stable or rising, neutrophil count stable or rising), and a decrease in serum ferritin by at least 25% from baseline.

If these criteria are met, continue Tier 1 therapy and begin a gradual taper after 7-14 days of clinical stability. If criteria are not met, proceed to Tier 2.

Tier 2: Combination Immunosuppression

Tier 2 therapy is indicated for cats that fail to respond to Tier 1 therapy within 72 hours, those with moderate organ dysfunction (elevated liver enzymes greater than three times the upper reference limit, mild coagulopathy with PT or aPTT prolonged less than 1.5 times normal), or those with severe cytopenias at presentation (hemoglobin less than 7 g/dL, platelets less than 50,000/microliter, neutrophils less than 1,000/microliter).

Add cyclosporine at 5-10 mg/kg orally every 12-24 hours to the corticosteroid regimen. Therapeutic drug monitoring is recommended to maintain trough levels between 300-500 ng/mL. Continue dexamethasone or prednisolone at the same dose.

Response assessment should occur at 72-96 hours after initiating combination therapy. Criteria for adequate response are the same as for Tier 1. If response is adequate, continue combination therapy and begin tapering corticosteroids first after 14-21 days of stability, followed by cyclosporine taper over 4-8 weeks. If response is inadequate, proceed to Tier 3.

Tier 3: Rescue Therapy and Referral

Tier 3 therapy is indicated for cats that fail Tier 2 therapy within 96 hours, those with severe organ dysfunction (acute kidney injury with creatinine greater than 2.5 mg/dL, disseminated intravascular coagulation, respiratory failure requiring oxygen support), or those with progressive cytopenias despite combination therapy.

At this stage, referral to a veterinary internist or specialty center is strongly recommended. Additional immunosuppressive agents that may be considered under specialist guidance include mycophenolate mofetil at 10-15 mg/kg orally every 12 hours, or leflunomide at 2-4 mg/kg orally every 24 hours. Cytotoxic agents such as etoposide or cyclophosphamide are rarely used in cats due to significant toxicity risks, but may be considered in refractory cases under specialist supervision. In human patients with secondary hemophagocytic syndrome, etoposide treatment has been associated with increased occurrence of healthcare-associated infections, while no association with survival was found (source: Annals of Intensive Care, 2022, https://doi.org/10.1186/s13613-022-01075-9). This risk should be carefully weighed in feline patients.

Response Assessment Record System

A standardized record system allows for objective tracking of response to therapy and early identification of treatment failure. The following parameters should be recorded at baseline and at each reassessment point.

Daily Monitoring Parameters

Record temperature twice daily, noting the highest temperature each day. Record mentation score using a simple scale: 0 for bright and alert, 1 for mildly depressed but responsive, 2 for moderately depressed with reduced responsiveness, 3 for severely depressed or obtunded. Record appetite as a percentage of estimated daily caloric intake consumed. Record any transfusion requirements, including type and volume of blood products administered.

Laboratory Monitoring Schedule

Perform a complete blood count, serum biochemistry profile, and serum ferritin measurement at baseline, then every 48-72 hours for the first week, then weekly once the patient is stable. Coagulation testing (prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer) should be performed at baseline and repeated if coagulopathy is present or if clinical bleeding develops.

Response Scoring System

Assign points for each parameter to create a composite response score. For temperature, assign 0 points if less than 103.0 degrees Fahrenheit (39.4 degrees Celsius), 1 point if 103.0-104.0 degrees Fahrenheit (39.4-40.0 degrees Celsius), and 2 points if greater than 104.0 degrees Fahrenheit (40.0 degrees Celsius). For hemoglobin, assign 0 points if greater than 10 g/dL, 1 point if 8-10 g/dL, and 2 points if less than 8 g/dL. For platelet count, assign 0 points if greater than 100,000/microliter, 1 point if 50,000-100,000/microliter, and 2 points if less than 50,000/microliter. For neutrophil count, assign 0 points if greater than 2,500/microliter, 1 point if 1,500-2,500/microliter, and 2 points if less than 1,500/microliter. For serum ferritin, assign 0 points if less than 500 ng/mL, 1 point if 500-1,000 ng/mL, and 2 points if greater than 1,000 ng/mL.

A total score of 0-3 indicates good response, 4-6 indicates partial response, and 7-10 indicates poor response. A poor response at 72 hours should trigger escalation to the next treatment tier.

Troubleshooting Common Clinical Scenarios

Several clinical scenarios commonly arise during the management of feline MAS that require specific troubleshooting approaches.

Persistent Fever Despite Immunosuppression

If fever persists beyond 72 hours of Tier 1 therapy, first verify that the corticosteroid dose is adequate and being administered consistently. Check for concurrent infection by performing blood cultures, urine culture, and thoracic radiographs. Consider the possibility of an undiagnosed infectious trigger such as FIP, toxoplasmosis, or systemic fungal infection. If no infection is identified and fever persists, escalate to Tier 2 therapy. If fever persists despite Tier 2 therapy, reconsider the diagnosis and evaluate for alternative causes of fever such as neoplasia or drug reaction.

Worsening Cytopenias During Treatment

Worsening cytopenias during treatment may indicate inadequate immunosuppression, progression of hemophagocytosis, or drug toxicity. First, rule out drug-induced cytopenias by reviewing all medications. Cyclosporine and mycophenolate mofetil can cause bone marrow suppression in some cats. If drug toxicity is suspected, consider dose reduction or alternative agents. If cytopenias are due to inadequate immunosuppression, escalate to the next treatment tier. Consider bone marrow aspiration to reassess for hemophagocytosis and rule out infiltrative diseases such as lymphoma or histiocytic sarcoma.

Development of Coagulopathy

Coagulopathy in MAS results from consumptive coagulopathy, hepatic dysfunction, and thrombocytopenia. If coagulopathy develops or worsens during treatment, perform a complete coagulation panel including PT, aPTT, fibrinogen, and D-dimer. Administer fresh frozen plasma at 10-15 mL/kg if there is active bleeding or if PT or aPTT is greater than 1.5 times normal. Vitamin K1 at 1-2 mg/kg subcutaneously every 12 hours may be considered if there is concern for vitamin K deficiency, though this is rarely the primary cause. If coagulopathy is severe or progressive, escalate to Tier 3 therapy and consider referral.

Acute Kidney Injury

Acute kidney injury can develop in MAS due to prerenal azotemia from dehydration, cytokine-mediated renal inflammation, or drug toxicity. If creatinine rises during treatment, first assess hydration status and provide aggressive intravenous fluid therapy if the patient is dehydrated. Discontinue any potentially nephrotoxic medications such as aminoglycosides or nonsteroidal anti-inflammatory drugs. Monitor urine output and consider placement of a urinary catheter if oliguria or anuria develops. If acute kidney injury is severe (creatinine greater than 2.5 mg/dL) or progressive despite fluid therapy, escalate to Tier 3 therapy and consider referral for potential hemodialysis.

Gastrointestinal Signs

Vomiting, diarrhea, and anorexia are common in cats with MAS due to the underlying inflammatory state and medication side effects. If gastrointestinal signs develop, consider reducing the corticosteroid dose if the patient is stable, or switching to a different formulation such as prednisolone instead of dexamethasone. Administer antiemetics such as maropitant at 1 mg/kg subcutaneously every 24 hours or ondansetron at 0.5-1 mg/kg intravenously every 12 hours. Provide nutritional support via nasoesophageal or esophageal feeding tube if the cat is not eating adequately. If gastrointestinal signs are severe or persistent, evaluate for pancreatitis, gastrointestinal ulceration, or infectious enteritis.

Records and Measurements

Maintaining detailed records is essential for tracking response to therapy and making timely treatment decisions. The following records should be maintained for each case.

Daily Flow Sheet

Create a daily flow sheet that includes date, temperature (highest and lowest), heart rate, respiratory rate, mentation score, appetite percentage, fluid therapy rate and type, medications administered with doses and routes, transfusion requirements, and any complications or adverse events.

Laboratory Tracking Table

Maintain a table with dates and results for complete blood count parameters (hemoglobin, hematocrit, platelet count, neutrophil count, lymphocyte count), serum biochemistry parameters (ALT, AST, ALP, total bilirubin, creatinine, BUN, albumin, globulin), coagulation parameters (PT, aPTT, fibrinogen, D-dimer), and serum ferritin. Calculate the response score at each reassessment point and record it in the table.

Treatment Escalation Log

Document the date and time of each treatment escalation, the criteria that triggered the escalation, the new medications or doses initiated, and the response to the escalation. This log provides a clear record of clinical decision-making and can be useful for case review or referral communication.

Common Failure Patterns

Several failure patterns are commonly observed in the management of feline MAS. Recognizing these patterns allows for early intervention and improved outcomes.

Delayed Escalation

The most common failure pattern is delayed escalation of therapy. Veterinarians may be reluctant to increase immunosuppression due to concerns about infection risk or drug toxicity. However, inadequate immunosuppression allows the hyperinflammatory state to progress, leading to irreversible organ damage. The decision framework provided above should be followed strictly, with escalation occurring at the specified time points if response criteria are not met.

Inadequate Diagnostic Workup

Failure to identify the underlying trigger is a major cause of treatment failure. Even with effective immunosuppression, MAS will recur if the trigger persists. A thorough diagnostic workup should be completed as soon as the patient is stable enough to undergo testing. This includes infectious disease testing, imaging, and biopsy of affected organs. If no trigger is identified initially, repeat testing should be considered if the patient fails to respond to therapy or relapses during tapering.

Premature Tapering

Tapering immunosuppressive therapy too quickly can lead to relapse. Corticosteroids should be tapered gradually over 4-8 weeks, with close monitoring for recurrence of fever, cytopenias, or rising ferritin levels. If relapse occurs during tapering, return to the previous effective dose and taper more slowly. Cyclosporine should be tapered after corticosteroids have been successfully discontinued.

Inadequate Supportive Care

Supportive care is often overlooked in the management of MAS, but it is critical for maintaining organ function and preventing complications. Nutritional support, fluid therapy, and blood product transfusion should be provided proactively instead of reactively. Cats that are not eating should have a feeding tube placed early in the course of treatment.

Professional Escalation Criteria

Veterinarians should consider referral to a veterinary internist or specialty center in the following situations: failure to respond to Tier 2 therapy within 96 hours, development of severe organ dysfunction such as acute kidney injury, disseminated intravascular coagulation, or respiratory failure, need for advanced diagnostic testing such as bone marrow biopsy with immunohistochemistry or flow cytometry, suspicion of an underlying neoplastic trigger requiring chemotherapy, recurrent or refractory disease requiring long-term management, and cases where the veterinarian is uncomfortable with the level of immunosuppression required.

Welfare and Safety Context

The management of feline MAS involves significant welfare considerations. Affected cats experience fever, pain from organomegaly and inflammation, and the stress of hospitalization and repeated procedures. Immunosuppressive therapy carries risks of infection, drug toxicity, and metabolic complications. The decision to pursue aggressive treatment should be made in consultation with the owner, with clear communication about the prognosis, potential complications, and expected duration of therapy.

Cats that are not responding to therapy after 7-10 days of appropriate treatment have a poor prognosis, and euthanasia should be discussed as a humane option. Quality of life should be assessed regularly using validated tools, and treatment should be adjusted or discontinued if the cat is experiencing significant suffering without reasonable expectation of recovery.

The World Organisation for Animal Health provides guidelines for animal health and welfare that emphasize the importance of minimizing pain, distress, and suffering in veterinary patients (source: World Organisation for Animal Health, Animal Health and Welfare, https://www.woah.org/en/what-we-do/animal-health-and-welfare). These principles should guide clinical decision-making in the management of feline MAS.

Frequently Asked Questions

What is the difference between macrophage activation syndrome and hemophagocytic lymphohistiocytosis in cats?

Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) are closely related hyperinflammatory syndromes that share similar pathophysiology and clinical features. In human medicine, MAS is typically used to describe the condition when it occurs as a complication of rheumatic diseases, while HLH is used for primary genetic forms and secondary forms associated with infections and malignancies. In veterinary medicine, the terms are often used interchangeably, with MAS being the preferred term in cats. Both conditions involve uncontrolled activation of macrophages and T lymphocytes, leading to cytokine storm, fever, cytopenias, and organ dysfunction.

How is feline macrophage activation syndrome diagnosed?

The diagnosis of MAS in cats is based on a combination of clinical signs, laboratory abnormalities, and specific biomarker findings. Key diagnostic criteria include persistent fever unresponsive to antibiotics, cytopenias affecting at least two cell lines, hyperferritinemia, elevated soluble CD25, and hemophagocytosis on bone marrow aspirate or tissue biopsy. A complete diagnostic workup should also include infectious disease testing, imaging studies, and biopsy of affected organs to identify the underlying trigger.

What causes macrophage activation syndrome in cats?

MAS in cats is typically secondary to an underlying trigger that causes immune dysregulation. Common triggers include viral infections (FeLV, FIV, FIP), bacterial infections (hemoplasmosis, sepsis), fungal infections, protozoal infections (toxoplasmosis), neoplastic diseases (lymphoma, histiocytic disorders), and inflammatory diseases (immune-mediated hemolytic anemia, polyarthritis). In some cases, no trigger is identified despite thorough investigation.

What is the treatment for feline macrophage activation syndrome?

Treatment involves immunosuppressive therapy to control the hyperinflammatory state, supportive care to manage complications, and treatment of the underlying trigger. High-dose corticosteroids (dexamethasone or prednisolone) are the first-line immunosuppressive agents, with cyclosporine added in nonresponders. Supportive care includes intravenous fluids, blood product transfusion, antimicrobial therapy for documented infections, and nutritional support. Identifying and treating the underlying trigger is essential for long-term control.

What is the prognosis for cats with macrophage activation syndrome?

The prognosis is guarded to poor, with reported mortality rates of 50-70% even with appropriate treatment. Factors associated with a worse prognosis include severe pancytopenia, marked hyperferritinemia, coagulopathy, multiorgan dysfunction, and failure to identify or treat the underlying trigger. Cats that respond to immunosuppressive therapy within the first week have a better prognosis, but many require long-term immunosuppression and remain at risk for relapse.

Can macrophage activation syndrome be prevented in cats?

Prevention of MAS focuses on reducing the risk of underlying triggers. Vaccination against FeLV and FIV can reduce the risk of these viral infections. Prompt diagnosis and treatment of infectious diseases, inflammatory conditions, and neoplasia may prevent the development of MAS. However, MAS can still occur in cats without identifiable risk factors, and early recognition remains the most important factor for improving outcomes.

How is macrophage activation syndrome different from sepsis in cats?

MAS and sepsis share many clinical features, including fever, cytopenias, and organ dysfunction, making differentiation challenging. Sepsis is caused by a systemic bacterial infection and is characterized by positive blood cultures and a cytokine profile dominated by IL-6 and TNF-alpha. MAS is a hyperinflammatory syndrome driven by uncontrolled macrophage and T-cell activation, with characteristic findings of hyperferritinemia, elevated sCD25, and hemophagocytosis. Sepsis can trigger MAS, and the two conditions can coexist.

When should I refer a cat with suspected macrophage activation syndrome to a specialist?

Referral to a veterinary internist or specialist center is recommended when there is failure to respond to initial immunosuppressive therapy within 48-72 hours, development of severe complications such as disseminated intravascular coagulation or acute kidney injury, need for advanced diagnostic testing such as bone marrow biopsy or immunohistochemistry, suspicion of an underlying neoplastic trigger requiring chemotherapy, or recurrent or refractory disease requiring long-term management.

Related Veterinary Guides

• Cat
• Clinical Biochemistry Urinalysis
• Hypertrophic Cardiomyopathy In Cats
• Prescription Medicine For Cats
• Sneezing Cat Remedy

References and Further Reading

• www.merckvetmanual.com
• catvets.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Haemophagocytic syndrome and COVID-19.. Clinical rheumatology, 2021.
• Adult onset Still's Disease.. Medicina clinica, 2018.
• Characterization and Outcomes of Septic Shock Patients with Macrophage Activation-Like Syndrome: Prognostic Role of Hyperferritinemia and Description of Hemoadsorption in Refractory Hyperinflammatory Septic Shock.. Blood purification, 2026.
• Interrelation between miRNAs Expression Associated with Redox State Fluctuations, Immune and Inflammatory Response Activation, and Neonatal Outcomes in Complicated Pregnancy, Accompanied by Placental Insufficiency.. Antioxidants (Basel, Switzerland), 2022.
• Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand.. Journal of virology, 2007.
• Utility of systemic score as a prognosis marker and biologic treatment indication in adults with Still's disease.. Medicina clinica, 2026.
• Etoposide treatment in secondary hemophagocytic syndrome: impact on healthcare-associated infections and survival. Annals of Intensive Care, 2022.
• Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies. Annals of Hematology, 2025.
• Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS). Hematology/Oncology Clinics of North America, 2025.
• Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis. Orphanet Journal of Rare Diseases, 2022.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.